Powerful Medical Receives €40 Million IPCEI Grant — read the full story

PM Magazine

Doctor holding Roche cobas® pulse point-of-care device displaying PMcardio AI-powered ECG interpretation for real-time heart attack detection at the patient bedside.

PMcardio Expands Heart Attack Detection to Patient Bedside through Roche cobas® pulse Point of Care Platform

Powerful Medical has partnered with Roche to integrate AI-powered ECG interpretation from PMcardio into the cobas® pulse point-of-care platform. Combined with Roche’s Elecsys® high-sensitivity cardiac Troponin T assay, this solution enables clinicians to rapidly and accurately rule in or rule out heart attacks directly at the patient’s bedside.

Editor's Choice

Independent RCT and Late-Breaking Science: PMcardio to Take Center Stage at TCT 2025

6. October 2025
Powerful Medical awarded €40M IPCEI grant to expand AI diagnostics for heart attacks, heart failure, and arrhythmias

Powerful Medical Receives €40 Million Non-Dilutive Grant to Accelerate Early Diagnosis of Cardiovascular Diseases with AI

28. July 2025
Collage showing a conference speaker, PMcardio app UI, hospital partnerships across Europe, and a research award ceremony.

May Highlights from Powerful Medical: PMcardio 3.0 Launch, STEMI Research, and Clinical Breakthroughs

7. June 2025

Independent RCT and Late-Breaking Science: PMcardio to Take Center Stage at TCT 2025

We’re proud to share that PMcardio and the Queen of Hearts™ (STEMI AI ECG model) will be prominently featured at Transcatheter Cardiovascular Therapeutics (TCT) 2025, the largest interventional cardiology conference in the U.S., taking place October 25–27, 2025 in San Francisco, California.
Doctor holding Roche cobas® pulse point-of-care device displaying PMcardio AI-powered ECG interpretation for real-time heart attack detection at the patient bedside.

PMcardio Expands Heart Attack Detection to Patient Bedside through Roche cobas® pulse Point of Care Platform

Powerful Medical has partnered with Roche to integrate AI-powered ECG interpretation from PMcardio into the cobas® pulse point-of-care platform. Combined with Roche’s Elecsys® high-sensitivity cardiac Troponin T assay, this solution enables clinicians to rapidly and accurately rule in or rule out heart attacks directly at the patient’s bedside.
Powerful Medical awarded €40M IPCEI grant to expand AI diagnostics for heart attacks, heart failure, and arrhythmias

Powerful Medical Receives €40 Million Non-Dilutive Grant to Accelerate Early Diagnosis of Cardiovascular Diseases with AI

Powerful Medical announces it has been selected to receive over €40 million in non-dilutive funding from the European Commission’s IPCEI Tech4Cure initiative. This significant grant will accelerate global adoption and clinical validation of PMcardio®, the world’s first AI-powered platform enabling rapid and accurate diagnosis of heart attacks and other life-threatening cardiac conditions, dramatically expanding the company’s potential to save millions of lives worldwide.
Image is showing logos of the two companies mentioned in the text - PMcardio and Alphaiota

Alphaiota Expands Strategic Partnership with PMcardio to Launch First AI-Powered Heart Attack Diagnostic Platform in Saudi Arabia

Alphaiota and PMcardio announce the expansion of their strategic partnership to bring the first AI-powered heart attack diagnostic solution to the Kingdom of Saudi Arabia. Developed by Powerful Medical, a medical device manufacturer specializing in AI-driven cardiovascular diagnostics, PMcardio will be introduced by Alphaiota as the exclusive distributor in the region, marking a first-of-its-kind deployment in the Middle East.

Stay on the pulse with our newsletter

Your submission was successful